Associated Papers
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
40503459 (PubMed )
Supplement: mmc1.xlsx › Supplementary_Table_S2
Clinical Validation of Local Versus Commercial Genomic Testing in Cancer: A Comparison of Tissue and Plasma Concordance.
Faulkner LG et al.
Cancer Investigation, 2025
39989311 (PubMed )
Supplement: supplement_1.pdf
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
37483495 (PubMed )
Supplement: Table_2.xlsx › all_patients_lung
A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
Kong LR et al.
Nature Communications, 2020
32214092 (PubMed )
Supplement: 41467_2020_15318_MOESM1_ESM.pdf
A molecular pathological study of four cases of ciliated muconodular papillary tumors of the lung.
Kataoka T et al.
Pathology International, 2018
Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.
Ong M et al.
British Journal of Cancer, 2014
A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity.
Ai X et al.
Amino Acids, 2014
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2011
21531810 (PubMed )
Supplement: 10780432ccr103408-sup-ccr_10-3408_wu_t4.pdf
The structural impact of cancer-associated missense mutations in oncogenes and tumor suppressors.
Stehr H et al.
Molecular Cancer, 2011
21575214 (PubMed )
Supplement: 1476-4598-10-54-S3.XLS › mutations.txt
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Shukuya T et al.
Cancer Science, 2011
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Ichihara S et al.
International Journal of Cancer, 2007
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
Inukai M et al.
Cancer Research, 2006
Select a paper to view details